Remepy

The Future of Drugs: Embracing Hybrid Therapies As we look toward the future of medicine, a transformative shift is emerging: the rise of hybrid drugs. Similar to how Uber revolutionized transportation and Airbnb changed hospitality, hybrid drugs are set to become the standard in healthcare within the next five years. But what are hybrid drugs, and why do they represent the future of pharmaceutical care? What Are Hybrid Drugs? Hybrid drugs are innovative therapies that merge traditional pharmaceutical ingredients with non-pharmaceutical interventions. This may include integrating lifestyle changes, dietary adjustments, physical therapies, or technology-driven solutions like digital health apps into a cohesive treatment plan. The aim is to create a holistic approach to health, acknowledging that wellness extends beyond mere medication. Why Hybrid Drugs Make Sense Personalization of Care: The future of medicine is personalized. Patients have unique needs, and hybrid drugs allow for tailored interventions that consider individual lifestyles, genetics, and preferences, leading to better adherence and outcomes. Enhanced Efficacy: Combining drugs with non-pharmaceutical protocols can improve treatment effectiveness. For instance, a medication for anxiety could be paired with cognitive behavioral therapy techniques delivered via an app, resulting in better mental health outcomes. Cost-Effectiveness: By integrating lifestyle changes that promote health, hybrid drugs may reduce the need for long-term pharmaceutical interventions, ultimately lowering healthcare costs for individuals and systems alike. Patient Empowerment: Hybrid drugs encourage patients to actively participate in their health. By including non-pharmaceutical strategies, patients become more engaged in their treatment, leading to better self-management and outcomes. Addressing Complex Health Issues: Many health conditions are multifaceted, requiring more than just medication for resolution. Hybrid drugs facilitate a comprehensive approach that can address various aspects of a condition simultaneously, enhancing overall health and well-being. #Tech bio #Bio tech # healthtech Remepy

Join Remepy's Co-founder and Co-CEO, Michal Tsur, for this intriguing discussion about Israeli innovation in biotech!

There are 300M people world wide living with rare diseases. Today is rare disease day. Rare diseases are an important area of focus for us @ Remepy. I am hoping that our unique hybrid approach to drug development will improve care for certain rare diseases. https://lnkd.in/drJRFYHe

Check out this fascinating discussion of Moran Barak, Medical Director at Abbvie, and Or Shoval, Remepy's Co-CEO, on the Abbvie #FutureMedPodcast

We’re extremely excited to present data from?Remepy’s Butterfly study?—?the first-ever study on a?Hybrid Drug for Parkinson’s Disease?— at?AD/PD in Vienna! Amir Amedi, Nira Saporta (Rivner), and Shahar Shelly M.D will be at the conference,?revealing?groundbreaking insights and sharing more of Remepy's innovative?science. #ADPD2024 #Parkinsons #HybridDrugs #Remepy Merav Catalogna, PhD, Shira Molcho MD

So grateful and honored to have you as Remepy's board member!

What a wonderful week! Made so many new friends. #israel #healthtech #entrepreneurship 8400 The Health Network

Last night, all Remepies took a little break from developing Hybrid Drugs and became chefs for one night to compete in a cooking challenge. Two teams, one kitchen, and a lot of ingenuity created for us the perfect night out (unless you weren't on the winning team). We were surprised to discover the impressive cooking skills of some of the Remepies - Tzlil the pastry fairy, Nissim the Schnitzel king, and Shahar the Salmon whisperer! This morning, after we took off our aprons, we got back to harnessing our motivation for creating the new generation of modern medicine - with a lot of leftovers in the fridge. You can have a little taste through the pictures.

We are indeed so lucky!

Honored to give a keynote at The Israel Academy of Sciences and Humanities where I explored how the fusion of neuroscience and technology is revolutionizing medicine and reshaping our understanding of the brain. I presented some innovative sensory rehabilitation solutions—leveraging touch and sound to assist individuals with hearing loss, I also explored my work with Remepy on Parkinson’s, and other neurological conditions. By bridging neuroscience with digital therapeutics, we aim to enhance brain health and accessibility. I am passionate about making science accessible, and my research has helped reshape fundamental neuroscience theories. For example, I contributed to revising the Critical Periods Theory, which was foundational to the 1981 Nobel Prize in Physiology or Medicine. Thanks to the Israel Academy of Sciences and Humanities and the Adams Fellowships Program for this platform to advance scientific excellence. #Neuroscience #Innovation #AdamsConference #BrainResearch #ScienceAndTechnology #MultisensoryIntegration #BrainHealth #Parkinson Amir Amedi Ofek Salama Adi Snir Michal Tsur Or Shoval Photo credit: The Isreal Academy of Science and Humanities Photographer: Michal Fatal